In Lithuania, the Pharmacy Law was amended to add a disclosure obligation for marketing authorization holders (MAHs) regarding transfers of value (ToVs) to healthcare professionals (HCPs) or healthcare organizations (HCOs). The rules were approved by the Minister of Health on June 23, 2020.
Although many pharmaceutical companies were already reporting in line with the principles […]
A special fraud alert was issued by the Office of the Inspector General (OIG) on November 16, 2020 highlighting the potential fraud and abuse related to the offer or payment of remuneration for speaker programs by pharmaceutical and medical device companies. Speaker programs were defined by the OIG for purposes of the special fraud alert […]
Earlier this year, we published a blog highlighting the French Decree on ‘anti-gifts’ that was published on June 17, 2020.[1] Additional ‘orders’ related to the French ‘anti-gift’ provisions were issued on August 7, 2020.
The French “anti-gift” provisions strictly frame the conditions under which companies in the health […]
The landscape of meeting compliance needs within life sciences is changing. Today, life sciences organizations are rapidly shifting to a digital centric world. This is especially true for solutions aimed at the highly complex task of managing healthcare professional (HCP) engagements as well as meeting global transparency reporting obligations. These solutions are a […]
If your organization is like most these days, resources are tight and teams are lean. Efficiency becomes a key ingredient to an effective compliance program. Running lean doesn’t mean corners must be cut or best practices need to be sacrificed. Below are five ways to keep your healthcare professional (HCP) engagement process in […]
One of the key areas of focus for compliance teams is pre-empting and managing risk across the organization before it becomes a compliance issue. Given that there could be many different sources of risk, especially in large global organizations, compliance teams need access to tools that can […]
As engagements between life sciences companies and healthcare professionals (HCPs) become more frequent and complex, the financial ties associated with those engagements continue to create significant compliance risk for many life sciences organizations. While there are many benefits to increased HCP engagements, such as helping to design clinical trials, conducting continuing medical education, developing clinical […]
Building a transparency reporting program is easy. Building an effective transparency reporting program, however, is much more challenging. Partnering with over a hundred medical device and pharmaceutical companies, I have had a first-hand opportunity to build from scratch, enhance and overhaul numerous transparency programs focused on U.S. and global reporting requirements. Through my experience, I […]
The Centers for Medicare & Medicaid Services recently published their 2019 Open Payments data. In the 2019 report, which includes transactions that took place between Jan. 1 and Dec. 31, 2019, applicable manufacturers reported $10.03 billion in publishable payments, ownership, and investment interests to healthcare professionals (HCPs) and healthcare organizations (HCOs), which is approximately 680 […]
On June 17, 2020, an important decree related to “anti-benefits” was published in France, including the ministerial orders implementing this decree. The new rules contain changes in the regulatory framework for interactions between the industry and healthcare professionals (HCPs). A summary of the decree can be found below and a link to the full decree […]
